JCO Journals

JCO is seeking a clinical investigator and leader to serve as its next Editor-in-Chief. Submit your interest today to advance ASCO’s flagship & highly cited publication.

Submit your interest today: https://app.smartsheet.com/b/form/2448e4c7b7c34af69ff735a11affb305

‼️#GU26 simultaneous publication by @AarmstrongDuke et al: 

Trial Design and Objectives for Patients with Prostate Cancer: Recommendations From Prostate Cancer Working Group 4

Learn more: https://bit.ly/46dupmq

We are proud to name Zsofia Stadler, MD from
@mskcancercenter.bsky.social the next Editor-in-Chief of JCO Precision Oncology starting July 1st. Dr. Stadler’s expertise will drive the integration of genomics & AI into cancer research for improved patient outcomes. Read more: bit.ly/4aoLPyZ
#JCOPO

Dr. Pedro Barata of University Hospitals Seidman Cancer Center and Dr. Ugwuji Maduekwe of the Medical College of Wisconsin discuss the emergence of organ preservation in GEJ and gastric cancers on the latest episode of the ASCO Education #BytheBook Podcast.

Listen here: https://bit.ly/4tAUje4

JCO Global Oncology (JCO GO) guest editors Drs. Fabio Ynoe de Moraes & Paul Pearlman discuss JCO GO's Special Series featuring the investigators working to develop a new generation of innovations through the NCI’s Affordable Cancer Technologies Program.

Read more: https://bit.ly/4tr3vl9

The draft guideline update for "Breast Cancer Follow-Up After Primary Treatment" is now available. Help us refine these standards of care. Submit your feedback to @ascocancer.bsky.social by February 23!

Read & comment here: https://bit.ly/4ccwl2h
#bcsm #BreastCancer

Big news! Onyinye D. Balogun, MD, MSc joins JCO Global Oncology as the new Associate Editor!

We’re excited to have her expertise from @northwellhealth.bsky.social. Welcome, Dr. Balogun!
#JCOGO #GlobalOncology

We are thrilled to announce that Dr. Chiara Cremolini is joining the Journal of Clinical Oncology (JCO) as our newest Associate Editor!

Her expertise in colorectal oncology & clinical and translational research aligns perfectly with our mission to advance cancer care.

New #ASCO #JCO Cancer Stories: "A Chance to Heal with Cold Hard Steel" with host @mikkaelsekeres.bsky.social. Dr. Taylor Goodstein shares a powerful perspective on surgery, grief, and finding courage within our own fallibility.

Tune in: https://bit.ly/4rG0nQL

JCO Updated Stage IV NSCLC guidelines:
➡️ASCO Living Guideline: Stage IV NSCLC (With Drivers) https://bit.ly/49SWlye

➡️ASCO Living Guideline: Stage IV NSCLC (Without Drivers) https://bit.ly/4at28L1

Exciting news! Fabio Ynoe de Moraes, MD, PhD, MBA, of Queen’s University has been named Deputy Editor of JCO Global Oncology.

Dr. Moraes’ leadership will drive #JCOGO’s mission to improve cancer care access and equity worldwide.

Join us in congratulating Dr. Moraes!
#GlobalOncology

#Telehealth has been a huge boon to oncology: save pts time, see people who might not be able to travel.

Q in new study @jco-asco.bsky.social: is "webside manner" affecting quality? Are we just adding extra appts?

A: Largely, no! Similar communication, slight ⬆️ appts.

ascopubs.org/doi/full/10....

We are thrilled to welcome Dr. Hsu as the new Editor-in-Chief of the ASCO Educational Book. A leader at UCSF and the San Francisco VA, Dr. Hsu aims to evolve the journal by embracing new formats to contextualize emerging oncology discoveries. Welcome!

In the latest #JCO Cancer Stories with host Dr. @mikkaelsekeres.bsky.social

Dr. Henry Bair shares a moving account of how vision care can honor end-of-life goals—helping a patient with failing sight write to his children.

Listen here: https://bit.ly/3ZxVYD9
#ArtOfOncology

When an oncologist leaves a rural community, the vacancy is more than a line item on a HR report. A new #JCOOP study explores the repercussions of specialist scarcity.

Listen to the full podcast with @fumikochino.bsky.social, Dr. Erika Moen & Dr. Dan Zuckerman: ascopubs.org/do/understaf...

New @ascocancer.bsky.social mCRPC living guideline updated recommendations for systemic therapy are here! For patients w/ visceral metastases (lung/liver), enzalutamide or docetaxel is advised, regardless of HRR status.

Stay current on mCRPC care: brnw.ch/21wZfuI

Check out JCO Precision Oncology's new TAPUR Study Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry. Learn more: brnw.ch/21wZ9I0

Addressing Common Medications That Influence Immunotherapy Response in Solid Tumors

Here is our publication in @jco-asco.bsky.social! We describe how common medications impact immunotherapy, how this affects practice and patients today, and outline ways to leverage this knowledge toward improved patient as well as our understanding of tumor immunology.

ascopubs.org/doi/10.1200/...

Attending ASCO #GI26? Join the Pathways to Publication Luncheon to meet the JCO Journals editorial team.

Get tips on peer review & publishing your manuscript. Limited space—first come, first served!

📅 Jan 9 | 11:45 AM PT | Level 3, Room 3005

Just published in #JCO, @jmikhaelmd.bsky.social & @lisakhicks.bsky.social introduce a new @ascocancer.bsky.social living guideline w/ updated recommendations for multiple myeloma therapy in differing variants and pt populations.

Learn more: brnw.ch/21wYSoe

Patil et al’s phase II study of seribantumab in tumors harboring NRG1 fusions supports the anti-tumor activity and safety of seribantumab in patients with advanced solid tumors harboring NRG1 fusions.

Read the full article. ascopubs.org/doi/abs/10.1...

Nassar et al’s study demonstrates high concordance of Recurrence Score® (RS) results between paired core needle biopsy (CNB) and surgical excision (SE) samples, which supports use of CNB for Oncotype DX® testing.

Read the full article. ascopubs.org/doi/abs/10.1...
#BreastCancer #bcsm

Listen to the latest #ASCO #JCO Cancer Stories: The Art of Oncology with host @mikkaelsekeres.bsky.social.

In this episode "Smell” with Dr. Cusick shares a connection to a cancer patient manifested as a scent.

🎧: ascopubs.org/do/smell-sce...

Simultaneous publication at #SABCS25! Horimoto et al.'s real-world data explores the clinical relevance of HER2 mutations in the efficacy of Trastuzumab Deruxtecan for HER2-low metastatic breast cancer.

👉 See the analysis: ascopubs.org/doi/abs/10.1...

#BreastCancer

🚨 HER2+ MBC Maintenance News! 🚨
The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance.
👉 See the results: ascopubs.org/doi/abs/10.1...

#HER2Positive #BreastCancer

Why it matters for #bladdercancer care: better risk-adapted bladder-sparing strategies, smarter use of biomarkers in decision-making, and trials built around what matters most to patients & survivors. #uroonc #MIBC

Key points 🗝️ addressed:
🔹 Standardizing non-operative trial design
🔹 Defining cCR, EFS and bladder-intact outcomes
🔹Integrating imaging & ctDNA biomarkers
🔹Embedding PROs and the patient voice

Milan Consensus Endpoints for Bladder Preservation in MIBC | Podcast | ASCO Publications Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article

🎧 New #JCOAfterHours episode! Dr. Davide Soldato sits down with Dr. Andrea Necchi & Dr. Ashish Kamat to discuss their @ascocancer.bsky.social article on evolving end points for non-operative #MIBC trials and bladder-sparing strategies.

Listen here: ascopubs.org/do/milan-con...

New data may reshape early-stage Triple-Negative Breast Cancer (TNBC) care!

Simultaneous publication at #SABCS25: The Phase III RJBC 1501 trial (Shen et al.) confirms/challenges the role of Carboplatin in adjuvant EC Taxane.

👉 Read the results: ascopubs.org/doi/abs/10.1...
#TNBC #BreastCancer

🚨 NEW DATA ALERT! 🚨 The Phase III BRUIN CLL-313 trial (Pirtobrutinib vs. BR) in untreated CLL/SLL was presented for simultaneous publication at #ASH25! You won't want to miss this!
Learn more: ascopubs.org/doi/abs/10.1...
#CLL #SLL